showed that inhibition of NMO-IgG-induced upregulation of CCL2 could maintain environmental homeostasis, reduce inflammation, and alleviate the deterioration of NMO lesions, suggesting CCL2 may be a promising candidate target for the NMOSD therapy. The gene discussed is CCL2; the disease is neuromyelitis optica.